Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Boehringer Ingelheim
Harvard Business School
McKesson
Mallinckrodt

Last Updated: May 19, 2022

Details for New Drug Application (NDA): 207318


✉ Email this page to a colleague

« Back to Dashboard

NDA 207318 describes NUPLAZID, which is a drug marketed by Acadia Pharms Inc and is included in two NDAs. It is available from one supplier. There are fourteen patents protecting this drug. Additional details are available on the NUPLAZID profile page.

The generic ingredient in NUPLAZID is pimavanserin tartrate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
Summary for 207318
Tradename:NUPLAZID
Applicant:Acadia Pharms Inc
Ingredient:pimavanserin tartrate
Patents:11
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 207318
Generic Entry Date for 207318*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 207318
Suppliers and Packaging for NDA: 207318
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NUPLAZID pimavanserin tartrate TABLET;ORAL 207318 NDA ACADIA Pharmaceuticals Inc 63090-100 63090-100-30 30 TABLET, COATED in 1 BOTTLE, PLASTIC (63090-100-30)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrengthEQ 17MG BASE
Approval Date:Apr 29, 2016TE:RLD:Yes
Patent:See Plans and PricingPatent Expiration:Jan 15, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
Patent:See Plans and PricingPatent Expiration:Apr 29, 2030Product Flag?YSubstance Flag?YDelist Request?
Patent:See Plans and PricingPatent Expiration:Aug 24, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS

Expired US Patents for NDA 207318

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.